A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
3期
已完成
NCT06238817
| 适应症 | Atopic Dermatitis |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Incyte Corporation |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 241 人 |
|---|
| 干预（药物） | Ruxolitinib Cream, Vehicle Cream |
|---|
| 开始日期 | 2024年4月26日 |
|---|
| 完成日期 | 2025年5月21日 |
|---|
| 结果公布日 | 2026年5月22日 |
|---|
摘要
This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
Percentage of Participants Achieving a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) at Week 8
Baseline; Week 8 · percentage of participants
| Vehicle Cream | 18.5 percentage of participants |
|---|
| Ruxolitinib 1.5% Cream | 70.0 percentage of participants |
|---|
| p-value | <0.0001 |
|---|
| Odds Ratio (OR) | 11.26 (95% CI 5.692–22.260) |
|---|
Percentage of Participants With Investigator's Global Assessment Treatment Success (IGA-TS) at Week 8
Baseline; Week 8 · percentage of participants
| Vehicle Cream | 13.6 percentage of participants |
|---|
| Ruxolitinib 1.5% Cream | 61.3 percentage of participants |
|---|
| p-value | <0.0001 |
|---|
| Odds Ratio (OR) | 10.14 (95% CI 4.904–20.975) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。